Biopharmaceutical IndustryFortrea said the acquisition will bring Worldwide’s clinical pharmacology unit and bioanalytical laboratory operations into its clinical pharmacology services business unit. The transaction is aimed at adding early-phase capacity and reducing handoffs between clinical and bioanalytical functions, while Worldwide plans to use the proceeds to support its late-stage focus areas.
Dr. Priya Nandakumar·Sep 3, 2026
Biotech InnovationIn the 50-patient study, adults with celiac disease received TEV ’408 or placebo before a six-week daily gluten challenge. Teva said the antibody significantly reduced intestinal damage versus placebo and reported no safety signals, while signaling that additional phase 2 work is needed before a phase 3 program can proceed.
Dr. Priya Nandakumar·Sep 3, 2026 
Regulatory & PolicyThe pact does not create entirely new SEC powers, but it gives both agencies a more formal mechanism to exchange non-public information and route requests through designated points of contact. For biopharma companies, the practical implication is a tighter link between what is said to investors and what the FDA may know about clinical trials, approvals, and other regulated events.
Dr. Priya Nandakumar·Sep 2, 2026 
Biopharmaceutical IndustryArsenal Biosciences said a "significant strategic shift" will leave it with a core team focused on in vivo CAR-T therapies. At the same time, the company is seeking strategic opportunities for its existing technology and assets after dropping prior lead programs from its pipeline.
Dr. Priya Nandakumar·Sep 2, 2026 
Biopharmaceutical IndustryThe update gives GSK a new shot at rebuilding a flu vaccine business that shrank by about 25% last year amid competitive pressure in the U.S. It also sharpens the next competitive question in mRNA flu: whether adding neuraminidase to the antigen mix can improve on first-generation products that focus mainly on hemagglutinin.
Dr. Priya Nandakumar·Sep 1, 2026 
Biopharmaceutical IndustryTakeda’s latest approval adds a second recent launch to what Jefferies described as the company’s next growth cycle. For Mimrylo, the commercial signal is less the approval itself than the scope of the label, which Jefferies said does not require prior treatment with medications that lower blood cell counts.
Dr. Priya Nandakumar·Sep 1, 2026 
Biopharmaceutical IndustryThe stopped study tested whether autogene cevumeran, also known as BNT122, could prevent recurrence after surgery by targeting each patient’s tumor mutations. Instead, Genentech confirmed there were more deaths in the vaccine arm in this patient population, shifting attention to whether the platform’s future depends on combination use rather than standalone treatment.
Dr. Priya Nandakumar·Aug 29, 2026 
Regulatory & PolicyThe FDA said the determination is not an approval or endorsement, and that people who do not smoke should not use Juul or other e-cigarettes. The policy signal is that the agency is still willing to authorize nicotine products when the record supports adult cigarette harm reduction, even as youth-use controls remain central to the commercial case.
Dr. Priya Nandakumar·Aug 29, 2026 
Regulatory & PolicyLilly supported the filing with the SURPASS-CVOT trial, which enrolled 13,000 participants across 30 countries over more than four and a half years. Mounjaro showed non-inferiority to Trulicity, with an 8% lower rate of cardiovascular death, heart attack or stroke in the study.
Dr. Priya Nandakumar·Aug 28, 2026 
Biopharmaceutical IndustryFrance’s Osivax will lead development of a combination vaccine pairing its influenza A candidate OVX836 with GC Biopharma’s inactivated seasonal flu vaccine, GC FLU. The agreement gives Osivax the components it needs to move from separate injections toward a single product that it believes could broaden protection while avoiding the friction of two shots.
Dr. Priya Nandakumar·Aug 27, 2026 
AI in Drug DiscoveryFlagship Pioneering’s ProFound Therapeutics has partnered with the Gates Foundation in a pact worth up to $35 million focused on preeclampsia, a high-blood-pressure disease of pregnancy that can be fatal for mother or child if not addressed. The collaboration pairs ProFound’s proteomics repository with an agentic AI tool meant to help assign function to newly identified targets before laboratory validation.
Dr. Priya Nandakumar·Aug 27, 2026 
Healthcare InvestmentThe agreement includes $400 million in near-term cash, up to $150 million in development and regulatory milestones, and the assumption of milestone obligations linked to Biohaven’s 2022 Knopp Biosciences agreement. For Biohaven, the deal strengthens the balance sheet as investors await data from the Phase 2/3 RISE3 trial in focal epilepsy.
Dr. Priya Nandakumar·Aug 26, 2026 